Format

Send to

Choose Destination
Chest. 2005 Apr;127(4):1312-26.

Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy.

Author information

1
University of Wisconsin, Madison Medical School, Department of Medicine, 15/220 Clinical Science Center, 600 Highland Ave, Madison, WI 53792-2454, USA. wwb@medicine.wisc.edu

Abstract

Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.

PMID:
15821210
DOI:
10.1378/chest.127.4.1312
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center